PMID- 34079314 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 1178-7007 (Print) IS - 1178-7007 (Electronic) IS - 1178-7007 (Linking) VI - 14 DP - 2021 TI - The Association Between Insulin Resistance, Leptin, and Resistin and Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients with Different Body Mass Indexes. PG - 2357-2365 LID - 10.2147/DMSO.S305054 [doi] AB - AIM: This study aimed to compare HOMA-IR, leptin, and resistin as the risk factors for diabetic nephropathy in the type 2 diabetes mellitus (T2DM) patients with different BMI classifications. MATERIALS AND METHODS: A total of 309 patients with T2DM were enrolled in this cross-sectional study. All participants were divided into three groups according to BMI: the normal weight group (18.5 kg/m(2)/=28 kg/m(2)). The clinical information and laboratory examinations were recorded in detail. Leptin and resistin levels were measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: Higher HOMA-IR, leptin and resistin levels were found to be the risk factors for diabetic nephropathy when we made comparisons in the total population (P<0.05). In the normal weight group, logistic regression analysis showed that T2DM patients with higher HOMA-IR (OR=4.210, P=0.001), leptin (OR=2.474, P=0.031) and resistin levels (OR=8.299, P<0.001) had nearly 4-fold, 2-fold and 8-fold risk for diabetic nephropathy, respectively, after adjustments. The receiver operating characteristic (ROC) curves indicated that the area under the curves (AUCs) of HOMA-IR and resistin were 0.699 (95% CI 0.617-0.772) and 0.790 (95% CI 0.715-0.854), respectively, which were significantly larger than the AUC of 0.5 (all P<0.001). However, no significant association was observed between HOMA-IR, leptin, and resistin and renal complications (all P>0.05) in the overweight and obesity groups in both logistic regression and AUC analysis. CONCLUSION: Higher insulin resistance, leptin and resistin levels were observed as risk factors for diabetic nephropathy in T2DM patients with lower BMI. These were not obvious in the overweight and obese patients. CI - (c) 2021 Huang et al. FAU - Huang, Jiaojiao AU - Huang J AD - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China. FAU - Peng, Xuemin AU - Peng X AD - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China. FAU - Dong, Kun AU - Dong K AD - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China. FAU - Tao, Jing AU - Tao J AD - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China. FAU - Yang, Yan AU - Yang Y AUID- ORCID: 0000-0001-8146-8040 AD - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China. LA - eng PT - Journal Article DEP - 20210524 PL - New Zealand TA - Diabetes Metab Syndr Obes JT - Diabetes, metabolic syndrome and obesity : targets and therapy JID - 101515585 PMC - PMC8163637 OTO - NOTNLM OT - diabetic nephropathy OT - insulin resistance OT - leptin OT - resistin OT - type 2 diabetes mellitus COIS- The authors declare that they have no conflicts of interest, financial or otherwise. EDAT- 2021/06/04 06:00 MHDA- 2021/06/04 06:01 PMCR- 2021/05/24 CRDT- 2021/06/03 06:37 PHST- 2021/02/02 00:00 [received] PHST- 2021/04/15 00:00 [accepted] PHST- 2021/06/03 06:37 [entrez] PHST- 2021/06/04 06:00 [pubmed] PHST- 2021/06/04 06:01 [medline] PHST- 2021/05/24 00:00 [pmc-release] AID - 305054 [pii] AID - 10.2147/DMSO.S305054 [doi] PST - epublish SO - Diabetes Metab Syndr Obes. 2021 May 24;14:2357-2365. doi: 10.2147/DMSO.S305054. eCollection 2021.